| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11154-017-9408-1 |
| P698 | PubMed publication ID | 28130634 |
| P50 | author | Ángela Fernández-Iglesias | Q89934944 |
| Enrique Rodríguez-Rubio | Q89934947 | ||
| P2093 | author name string | F Santos | |
| O Hernández | |||
| D Claramunt-Taberner | |||
| H Gil-Peña | |||
| L Alonso-Durán | |||
| R Fuente | |||
| P2860 | cites work | A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium | Q24308202 |
| Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations | Q24595718 | ||
| Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia | Q24623628 | ||
| The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis | Q24625902 | ||
| Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism | Q26852624 | ||
| Regulation and function of the FGF23/klotho endocrine pathways | Q26860470 | ||
| X-linked hypophosphataemia: a homologous disorder in humans and mice | Q28138350 | ||
| Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23 | Q28209679 | ||
| Klotho converts canonical FGF receptor into a specific receptor for FGF23 | Q28272505 | ||
| Osteoclastic metabolism of 25(OH)-vitamin D3: a potential mechanism for optimization of bone resorption | Q28291550 | ||
| alpha-Klotho as a regulator of calcium homeostasis | Q28306317 | ||
| Genetic ablation of parathyroid glands reveals another source of parathyroid hormone | Q28508870 | ||
| FGF23 promotes renal calcium reabsorption through the TRPV5 channel | Q28509196 | ||
| Downregulation of NaPi-IIa and NaPi-IIb Na-coupled phosphate transporters by coexpression of Klotho | Q28571743 | ||
| Regulation of fibroblast growth factor-23 signaling by klotho | Q28587100 | ||
| Effect of growth hormone treatment on final height, phosphate metabolism, and bone mineral density in children with X-linked hypophosphatemic rickets | Q31928471 | ||
| Hypophosphatemia leads to rickets by impairing caspase-mediated apoptosis of hypertrophic chondrocytes | Q33892284 | ||
| The Fibroblast Growth Factor signaling pathway | Q34467171 | ||
| Proximal tubular handling of phosphate: A molecular perspective | Q34563763 | ||
| Altered renal FGF23-mediated activity involving MAPK and Wnt: effects of the Hyp mutation | Q34632352 | ||
| Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype | Q34718202 | ||
| Rescue of the skeletal phenotype in CasR-deficient mice by transfer onto the Gcm2 null background | Q34890442 | ||
| FGF-23 regulates CYP27B1 transcription in the kidney and in extra-renal tissues | Q34982729 | ||
| Hypophosphatemia: mouse model for human familial hypophosphatemic (vitamin D-resistant) rickets | Q35044977 | ||
| Fibroblast growth factor 23 regulates renal 1,25-dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in Hyp mice | Q35538411 | ||
| Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23. | Q35829300 | ||
| Parathyroid hormone activation of the 25-hydroxyvitamin D3-1alpha-hydroxylase gene promoter | Q35859594 | ||
| Chronic inhibition of ERK1/2 signaling improves disordered bone and mineral metabolism in hypophosphatemic (Hyp) mice | Q35872763 | ||
| Fibroblast growth factor 21 (FGF21) inhibits chondrocyte function and growth hormone action directly at the growth plate | Q36122162 | ||
| The renal phosphate transport defect in normal mice parabiosed to X-linked hypophosphatemic mice persists after parathyroidectomy | Q69800707 | ||
| Nephrocalcinosis and its relationship to treatment of hereditary rickets | Q69809922 | ||
| Effects of calcitriol and phosphorus therapy on the growth of patients with X-linked hypophosphatemia | Q70660338 | ||
| Renal Na(+)-phosphate cotransporter gene expression in X-linked Hyp and Gy mice | Q71219174 | ||
| Growth in familial hypophosphatemic vitamin-D-resistant rickets | Q72426619 | ||
| Osteomalacia in hyp mice is associated with abnormal phex expression and with altered bone matrix protein expression and deposition | Q73400284 | ||
| Growth hormone normalizes renal 1,25-dihydroxyvitamin D3-24-hydroxylase gene expression but not Na+-phosphate cotransporter (Npt2) mRNA in phosphate-deprived Hyp mice | Q73794657 | ||
| Effect of gene dose and parental origin on bone histomorphometry in X-linked Hyp mice | Q75363694 | ||
| Mutational analysis of PHEX gene in X-linked hypophosphatemia | Q77398352 | ||
| A trial of growth hormone therapy in well-controlled hypophosphataemic rickets | Q78196734 | ||
| Isolation of renal proximal tubular brush-border membranes | Q80422705 | ||
| Age-related stature and linear body segments in children with X-linked hypophosphatemic rickets | Q82680331 | ||
| CYP24 inhibition as a therapeutic target in FGF23-mediated renal phosphate wasting disorders | Q36515176 | ||
| Pathogenic role of Fgf23 in Dmp1-null mice. | Q36846110 | ||
| Mineral metabolism and bone abnormalities in children with chronic renal failure | Q37050485 | ||
| Inherited hypophosphatemic disorders in children and the evolving mechanisms of phosphate regulation | Q37118591 | ||
| The Na+-Pi cotransporter PiT-2 (SLC20A2) is expressed in the apical membrane of rat renal proximal tubules and regulated by dietary Pi | Q37162336 | ||
| Pex/PEX tissue distribution and evidence for a deletion in the 3' region of the Pex gene in X-linked hypophosphatemic mice | Q37364983 | ||
| Therapeutic management of hypophosphatemic rickets from infancy to adulthood. | Q37648693 | ||
| Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia | Q37679946 | ||
| Phosphate homeostasis and the renal-gastrointestinal axis | Q37763810 | ||
| Hypophosphatemia and growth | Q38062345 | ||
| Genetic diseases of renal phosphate handling | Q38244118 | ||
| Regulation of cellular transport by klotho protein | Q38281526 | ||
| Phosphate homeostasis and genetic mutations of familial hypophosphatemic rickets | Q38430631 | ||
| Bone kidney interactions | Q38544166 | ||
| Klotho/fibroblast growth factor 23- and PTH-independent estrogen receptor-α-mediated direct downregulation of NaPi-IIa by estrogen in the mouse kidney | Q38770066 | ||
| Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment. | Q38920680 | ||
| FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone | Q39496020 | ||
| The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel | Q40359636 | ||
| Cloning and characterization of the proximal murine Phex promoter | Q40784655 | ||
| Bone mineral density of the spine and radius shaft in children with X-linked hypophosphatemic rickets (XLH). | Q42094408 | ||
| Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia | Q44203982 | ||
| Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets | Q44547503 | ||
| Effect of GH replacement therapy in two male siblings with combined X-linked hypophosphatemia and partial GH deficiency | Q44599553 | ||
| Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis | Q44779387 | ||
| Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. | Q45020373 | ||
| FGF23 is mainly synthesized by osteocytes in the regularly distributed osteocytic lacunar canalicular system established after physiological bone remodeling. | Q45956191 | ||
| Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice. | Q46279242 | ||
| Cartilage abnormalities are associated with abnormal Phex expression and with altered matrix protein and MMP-9 localization in Hyp mice | Q46285620 | ||
| Mechanism of longitudinal bone growth and its regulation by growth plate chondrocytes | Q46295189 | ||
| Vitamin D receptor genotype in hypophosphatemic rickets as a predictor of growth and response to treatment | Q46338629 | ||
| X-linked hypophosphatemia: a search for gender, race, anticipation, or parent of origin effects on disease expression in children | Q46852736 | ||
| Pathogenic role of Fgf23 in Hyp mice. | Q46921328 | ||
| Effects of growth hormone treatment on body proportions and final height among small children with X-linked hypophosphatemic rickets | Q47418048 | ||
| Differential effects of Npt2a gene ablation and X-linked Hyp mutation on renal expression of Npt2c | Q47650555 | ||
| Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia | Q47871507 | ||
| Pex gene deletions in Gy and Hyp mice provide mouse models for X-linked hypophosphatemia | Q48054327 | ||
| Sodium-phosphate transporter adaptation to dietary phosphate deprivation in normal and hypophosphatemic mice | Q49051216 | ||
| Serum FGF23 levels in normal and disordered phosphorus homeostasis. | Q51535459 | ||
| FGF23 Neutralizing Antibody Ameliorates Hypophosphatemia and Impaired FGF Receptor Signaling in Kidneys of HMWFGF2 Transgenic Mice. | Q51701483 | ||
| VITAMIN D-RESISTANT RICKETS. ANALYSIS OF TWENTY-FOUR PEDIGREES WITH HEREDITARY AND SPORADIC CASES. | Q54717149 | ||
| Phenotype Presentation of Hypophosphatemic Rickets in Adults | Q57727161 | ||
| X-linked hypophosphatemia: skeletal mass in adults assessed by histomorphometry, computed tomography, and absorptiometry | Q58086003 | ||
| Growth hormone therapy in hypophosphatemic rickets | Q68025101 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 107-115 | |
| P577 | publication date | 2017-03-01 | |
| P1433 | published in | Reviews in Endocrine and Metabolic Disorders | Q15766899 |
| P1476 | title | X-linked hypophosphatemia and growth | |
| P478 | volume | 18 |
| Q58802061 | Analysis of 2 novel mutations of PHEX gene inducing X-linked dominant hypophosphatemia rickets in 2 families: Two case reports |
| Q64039348 | Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia |
| Q52687353 | Genetic Causes of Rickets. |
| Q57148664 | Genetic Risk Factors for Atypical Femoral Fractures (AFFs): A Systematic Review |
| Q90080360 | Nationwide Hypophosphatemic Rickets Cohort Study |
| Q90284695 | New perspectives on the treatment of skeletal dysplasia |
| Q90056856 | Positive Response to One-Year Treatment With Burosumab in Pediatric Patients With X-Linked Hypophosphatemia |
| Q88708751 | X-linked hypophosphatemia with enthesopathy |
Search more.